Exenatide prevents fat-induced insulin resistance and raises adiponectin expression and plasma levels

Diabetes, Obesity and Metabolism

Volumn 10, Issue 10, 2008, Pages 921-930

  Li, Ling ^a   Yang, G ^a   Li, Q ^a   Tan, X ^a   Liu, H ^b   Tang, Y ^c   Boden, G ^d  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^c CENTOCOR INC   (United States)

^d TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adiponectin; Exenatide; Insulin sensitivity; Visfatin

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; CHOLESTEROL; EXENDIN 4; FATTY ACID; GLUCOSE; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; TRIACYLGLYCEROL; VISFATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY FAT; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFECT; FATTY ACID BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE; INSULIN CLEARANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; LIPID DIET; MALE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SKELETAL MUSCLE;

EID: 52449129375     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2007.00832.x     Document Type: Article

References (32)

1. Drucker DJ. Glucagon-like peptides. Diabetes 1998; 47: 159-169.
2. Drucker D. Minireview: The glucagon-like peptides. Endocrinology 2001; 142: 521-527.
3. Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): A potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 2004; 117: 77-88.
4. Young AA. Glucagon-like peptide-1, exendin and insulin sensitivity. In: Hansen B, Shafrir E, eds. Insulin Resistance and Insulin Resistance Syndrome. New York: Harwood Academic Press, 2002; 235-262.
5. Goke R, Fehmann HC, Linn T et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin secreting β-cells. J Biol Chem 1993; 268: 19650-19655.
6. Edwards C, Stanley S, Davis R et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 2001; 281: E155-E161.
7. Egan J, Clocquet A, Elahi D. The insulinotropic effect of acute exendin-4 administered to humans: Comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab 2002; 87: 1282-1290.
8. Montrose-Rafizadeh C, Yang H, Rodgers B et al. High potency antagonists of the pancreatic glucagon-like peptide-1 receptor. J Biol Chem 1997; 272: 21201-21206.
9. Young AA, Gedulin BR, Bhavsar S et al. Glucose-lowering and insulin-sensitizing actions of exendin-4: Studies in obese diabetic (ob/ ob, db/db) mice, diabetic fatty Zucker rats and diabetic rhesus monkeys (Macaca mulatta). Diabetes 1999; 48: 1026-1034.
10. Parkes D, Jodka C, Smith P et al. Pharmacokinetic actions of exendin-4 in the rat: Comparison with glucagon-like peptide-1. Drug Dev Res 2001; 53: 260-267.
11. Parkes DG, Pittner R, Jodka C, Smith P, Young A. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism 2001; 50: 583-589.
12. Kolterman OG, Buse JB, Fineman MS et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 3082-3089.
13. Gedulin BR, Nikoulina SE, Smith PA et al. Exenatide (exendin-4) improves insulin sensitivity and β-cell mass in insulin-resistant obese fa/ fa Zucker rats independent of glycemia and body weight. Endocrinology 2004; 146: 2069-2076.
14. Buse JB, Henry RR, Han J et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2628-2635.
15. Kolterman OG, Kim DD, Shen L et al. Pharmacokinetics, pharmacodynamics, and safety of a range of subcutaneous exenatide (exendin-4) doses in subjects with type 2 diabetes. Am J Health Syst Pharm 2005; 62: 173-181.
16. Bloom SR. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 2001; 281: E155-E161.
17. Gedulin B, Bhavsar S, Smith P, Young A. Acute restoration of glucose responsiveness of insulin secretion in diabetic fatty Zucker (ZDF) rats during infusion of exendin-4. Diabetologia 2000; 43: A148.
18. Fehse FC, Trautmann ME, Holst JJ et al. Effects of exenatide on first and second phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. Diabetes 2004; 53 (Suppl. 2): A82 (Abstract 351-OR).
19. McIntosh CHS, Pederson RA. Noninsulin-dependent animal models of diabetes mellitus. In: McNeill JH, ed. Experimental Models of Diabetes. Boca Raton, FL: CRC Press, 1999; 337-398.
20. Yang G, Li L, Tang Y, Boden G. Short-term pioglitazone treatment prevents free fatty acid-induced hepatic insulin resistance in normal rats: Possible role of the resistin and adiponectin. Biochem Biophys Res Commun 2006; 339: 1190-1196.
21. Cheung P, Yang G, Boden G. Milrinone, a selective phosphodiesterase 3 inhibitor, stimulates lipolysis, endogenous glucose production, and insulin secretion. Metabolism 2003; 52: 1496-1500.
22. Steele R, Wall JS, DeBodo RC. Measurement of size and turnover rate of body glucose pool by the isotope dilution method. Am J Physiol 1956; 187: 15-24.
23. Moorhouse JA, Grahame GR, Rosen NJ. Relationship between intravenous glucose tolerance and fasting blood glucose level in healthy and diabetic subjects. J Clin Endocrinol 1964; 24: 145-159.
24. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology 2007; 132: 2169-2180.
25. Despres J-P, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353: 2121-2134.
26. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. RIO-North America: A randomized controlled trial. JAMA 2006; 295: 761-775.
27. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997; 46: 3-10.
28. Boden G. Obesity, insulin resistance, type 2 diabetes and free fatty acids. Expert Rev. Endo. Metab. 2006; 1: 499-505.
29. Yamauchi T, Kamon J, Waki H. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7: 941-946.
30. Ahren B, Thomaseth K, Pacini G. Reduced insulin clearance contributes to the increased insulin levels after administration of glucagon-like peptide 1 in mice. Diabetologia 2005; 48: 2140-2146.
31. Meier JJ, Holst JJ, Schmidt WE, Nauck MA. Reduction of hepatic insulin clearance after oral glucose ingestion is not mediated by glucagon-like peptide 1 or gastric inhibitory polypeptide in humans. Am J Physiol Endocrinol Metab 2007; 293: E849-E856.
32. Li L, Yang G, Li Q et al. Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Exp Clin Endocrinol Diabetes 2006; 114: 544-548.